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We compared the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) for pa-
tients with relapsed or refractory Hodgkin lymphoma (HL) based on donor cell source. Ninety patients with
HL were treated with nonmyeloablative conditioning followed by HCT from HLA-matched related, n5 38,
unrelated, n5 24, or HLA-haploidentical related, n5 28 donors. Patients were heavily pretreated with a me-
dian of 5 regimens and most patients had failed autologous HCT (92%) and local radiation therapy (83%).
With a median follow-up of 25 months, 2-year overall survivals, progression-free survivals (OS)/(PFS), and
incidences of relapsed/progressive disease were 53%, 23%, and 56% (HLA-matched related), 58%, 29%,
and 63% (unrelated), and 58%, 51%, and 40% (HLA-haploidentical related), respectively. Nonrelapse mortal-
ity (NRM) was significantly lower for HLA-haploidentical related (P 5 .02) recipients compared to HLA-
matched related recipients. There were also significantly decreased risks of relapse for HLA-haploidentical
related recipients compared to HLA-matched related (P 5 .01) and unrelated (P 5 .03) recipients. The inci-
dences of acute grades III-IV and extensive chronic graft-versus-host disease (aGVHD, cGVHD) were 16%/
50% (HLA-matched related), 8%/63% (unrelated), and 11%/35% (HLA-haploidentical related). These data
suggested that salvage allogeneic HCTusing nonmyeloablative conditioning provided antitumor activity in pa-
tients with advancedHL; however, disease relapse/progression continued to bemajor problems. Importantly,
alternative donor stem cell sources are a viable option.
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Most patients with Hodgkin lymphoma (HL) are
cured with conventional chemotherapy 6 radiation
therapy. However, 10% to 20% of patients with
advanced HL will not achieve complete remission fol-
lowing first-line therapy, and 20% to 30% of patients
will relapse following complete remission [1]. Patients
with relapsed or refractory disease are often offered
salvage treatment with additional intensive chemo-
therapy followed by autologous hematopoietic cell
transplantation (HCT) or, less often, allogeneic HCT.
Unfortunately, many patients will relapse following
autologous HCT, and additional therapies are limited
[1-4]. Second autologous transplants are difficult
because of toxicities, lack of effectiveness, and prob-
lems with obtaining hematopoietic stem cells (HSC)1279
1280 Biol Blood Marrow Transplant 14:1279-1287, 2008L. M. Burroughs et al.for transplantation. Allogeneic transplants are appeal-
ing because of the potential graft-versus-lymphoma
(GVL) effects and a tumor-free graft. Initial studies
using myeloablative allogeneic HCT in patients who
have relapsed after autologous HCT found high
nonrelapse mortality (NRM) [5,6]. More recently,
Freytes et al. [7] reported a treatment-related mortal-
ity (TRM) of 22% for patients with HL or non-
Hodgkin lymphoma (NHL), and Devetten et al. [8]
reported Center for International Blood and Marrow
Transplant Research (CIBMTR) registry data demon-
strating a lower risk of TRM with nonmyeloablative
(relative risk [RR] 0.52, 95% confidence interval
[CI], 0.26-1.05) and reduced-intensity conditioning
(RIC) (RR 0.58, 95% CI, 0.31-1.07) regimens com-
pared to myeloablative regimens; however, this did
not reach statistical significance. Allogeneic HCT
after nonmyeloablative or RIC has also been used
as a treatment option for patients with progressive
HL who have failed autologous HCT [9-14]. Impor-
tantly, disease responses were seen in the setting of
decreased NRM.
Based on preclinical studies in the canine model at
the Fred Hutchinson Cancer Research Center
(FHCRC), a nonmyeloablative preparative regimen
consisting of 2 Gy total body irridiation (TBI) with
or without Flu followed by postgrafting immunosup-
pressionwithmycophenolatemofetil (MMF) and a cal-
cineurin inhibitor (cyclosporine) was developed [15].
This regimen has proved to be minimally toxic, well
tolerated, and potentially effective for patients with
malignant or nonmalignant hematologic diseases
who were ineligible for conventional HLA-matched
related or unrelated donor HCT [16-23].
However, many patients do not have HLA-
matched related or unrelated donors. Several studies
have described myeloablative HCT using related
HLA-haploidentical donors as a viable treatment
option for patients with hematologic malignancies;
however, inferior survivals were often seen because
of increased graft failure/rejection and other signifi-
cant toxicities including graft-versus-host diseaese
(GVHD) [24,25]. To enable HLA-haploidentical
HCT after nonmyeloablative conditioning, investiga-
tors at the Sidney Kimmel Comprehensive Cancer
Center (SKCCC) of Johns Hopkins University
expanded upon the FHCRC approach described above
by incorporating high-dose, posttransplantation
cyclophosphamide (cy) to achieve the selective deple-
tion of alloreactive T cells [26-29]. Specifically, no im-
munosuppressive drugs were given for the first 3 days
following marrow transplant to allow for expansion of
alloreactive clones of T cells, which were then killed by
administration of a dose of cyclophosphamide (cy). Af-
terward, immunosuppressive therapy with tacrolimus
and MMF was begun both for control of rejection
and GVHD. This regimen has been shown to be effec-tive in establishing engraftment with reduced toxicities
in high-risk patients with hematologic malignancies
[30-33].
Historically, donor type has correlated with out-
come, with HLA-matched related grafts having supe-
rior outcomes to unrelated and HLA-haploidentical
related grafts. Here we evaluated the utility of alloge-
neic HCT from either HLA-matched related, unre-
lated, or HLA-haploidentical related donors after
nonmyeloablative conditioning as treatment for 90
patients with HL who were ineligible for high-dose
conventional allogeneic HCT.
PATIENTS AND METHODS
Eligibility Criteria
This retrospective analysis included data from all
patients with HL who received HCT from HLA-
matched related (n 5 38), unrelated (n 5 24), or
HLA-haploidentical related (n 5 28) donors between
December 1998 and October 2007. Results were ana-
lyzed as of March 2008. Patients were treated at 12
centers on multi-institutional protocols that were ap-
proved by the institutional review boards of the
FHCRC and each collaborating center. All patients
signed consent forms approved by the local institu-
tional review boards. Patients with a diagnosis of HL
who were ineligible for or had failed autologous
HCTwere included. No exclusions were made for dis-
ease status or chemotherapy sensitivity.
Characteristics at HCT
Details regarding patient characteristics are pro-
vided in Table 1. Patients received a median number
of 5 preceding regimens. Most had preceding local ra-
diation therapy (83%) and had failed high-dose autol-
ogous/syngeneic HCT (92%). One candidate for an
HLA-haploidentical related graft had failed myeloa-
blative allogeneic HCT. Seven patients (4 HLA-
matched related, 3 unrelated) had planned autologous
HCT before allogeneic HCT to reduce disease
burden.
Patients were designated to be in complete remis-
sion (CR) if they had no identifiable disease on comput-
erized tomography (CT) scan 6 positron emission
tomography (PET) scan, in partial remission (PR) if
their disease had decreased by 50% following salvage
therapy, in untested relapse if they had relapsed
following salvage therapy, and as having refractory dis-
ease if they did not respond to or progressed despite
salvage therapy. The patients’ disease burdens were
categorized as either $5 cm or \5 cm of tumor
mass/lymphadenopathy. Comorbidities were assessed
using the HCT-Comorbidity Index (HCT-CI) [34].
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Patients and their donors were typed for HLA-A,
-B, or -C by at least intermediate-resolution DNA
typing, and -DRB1 and -DQB1 by high-resolution
techniques [35]. Five unrelated recipient/donor pairs
had single HLA-A, -B, or -C antigen mismatches. Of
these, 2 also had an additional HLA-A or -B allele mis-
match each. One additional unrelated recipient/donor
pair had a single HLA-B allele mismatch. For the
HLA-haploidentical related donors, the median num-
ber of mismatches both in the graft-versus-host
(GVH) and host-versus-graft (HVG) directions was 4.
Table 1. Patient and Disease Characteristics (n 5 90)
Characteristics
HLA-Matched
Related
(n 5 38)
Unrelated
(n 5 24)
HLA-Haploidentical
Related
(n 5 28)
Age
Median, in years
(range)
33 (17-64) 28 (20-45) 32 (14-62)
Sex, n (%)
Male 20 (53%) 12 (50%) 13 (46%)
Female 18 (47%) 12 (50%) 15 (54%)
CMV serostatus, n (%)
Recipient (–)
/Donor (–)
18 (47%) 6 (25%) 10 (36%)
Recipient (+)
/Donor (–)
6 (16%) 7 (29%) 4 (14%)
Recipient (–)
/Donor (+)
4 (11%) 5 (21%) 6 (21%)
Recipient (+)
/Donor (+)
10 (26%) 6 (25%) 8 (29%)
Time diagnosis –
allogeneic HCT
Median, in years
(range)
3 (1-34) 3 (1-17) 3 (1-18)
Prior treatment
Median lines
of treatment (range)
4 (2-9) 5 (3-10) 5 (3-10)
Local radiotherapy, n (%) 32 (84%) 22 (92%) 21 (75%)
Prior autologous HCT, n (%)
Failed 34 (89%)* 24 (100%)* 25† (89%)
Time from autologous
to allogeneic HCT
Median, in months
(range)
15 (4-110) 20 (8-144) 18† (5-73)
HCT-CI score, n (%)
0-1 14 (37%) 6 (26%) 11 (39%)
2+ 24 (63%) 17 (74%) 17 (61%)
Disease bulk at HCT, n (%)
<5 cm 32 (89%) 20 (87%) 24 (86%)
>5 cm 4 (11%) 3 (13%) 4 (14%)
Disease status at HCT, n (%)
CR 11 (29%) 5 (21%) 6 (21%)
PR 16 (42%) 8 (33%) 6 (21%)
Untested relapsed 3 (8%) 2(8%) 4 (14%)
Refractory 8 (21%) 9 (38%) 12 (43%)
Cell dose/kg, median (range) ‡
CD34 cells (106) 9.8 (2.8-43) 7.7 (2.3-25) 4.2 (1.7-16.2)
CD3 cells (108) 4.0 (1.0-68) 2.9 (0.8-10.7) 0.4 (0.2-0.8)
HCT indicates hematopoietic cell transplantation; HCT-CI, HCT-Co-
morbidity Index; CMV, cytomegalovirus.
*Planned tandem autologous/allogeneic HCT–related (n5 4), unrelated
(n 5 3).
†One candidate for an HLA-haploidentical related graft had failed mye-
loablative allogeneic HCT.
‡Graft composition was the only statistically significant difference
between the groups.Preparative Regimens and Postgrafting
Immunosuppression
The nonmyeloablative preparative regimen con-
sisted of either 2 Gy TBI (7 cGy/min; day 0) alone
(n 5 17, HLA-matched related) or combined with
fludarabine 30 mg/m2/day (days 24 to 22 [n 5 21,
HLA-matched related; all unrelated]) followed by
postgrafting immunosuppression with MMF or cyclo-
sporine/tacrolimus as previously described [16,22,36].
The 5 patients who received a 1 HLA antigen mis-
matched unrelated graft received slightly longer
courses of MMF (45 mg/kg/day; days 0 to 1100
then taper) and cyclosporine (days 23 to day 1180
then taper). The nonmyeloablative regimen for the
28 HLA-haploidentical related recipients consisted
of cy (14.5 mg/kg/day; days 26, 25), fludarabine (30
mg/m2/day; days 26 to 22), and 2 Gy TBI (7 cGy/
min; day 21). On day 13 (FHCRC) or on days 13
and 14 (SKCCC), cy (50 mg/kg/day) was given, fol-
lowed by additional postgrafting immunosuppression
with tacrolimus (targeted to a level of 5-15 ng/mL;
day 14 through day 184, then taper to day 180
[FHCRC] or day 15 through day 180 [SKCCC])
and MMF (45 mg/kg/day; day 14 [FHCRC] or 15
[SKCCC] to day 135). All HLA-haploidentical re-
lated recipients received filgrastim (Neupogen, Am-
gen, Thousand Oaks, CA), 5 mg/kg/day by
subcutaneous injection starting on day 11 (SKCCC)
or day 14 (FHCRC), until the absolute neutrophil
counts (ANC) were .500/mL for 3 days.
Collection of Hematopoietic Cells and
Supportive Care
All HLA-matched related and unrelated recipients
received granulocyte colony stimulating factor
(G-CSF) mobilized peripheral blood mononuclear
cells (PBMC) as the stem cell product, whereas all
HLA-haploidentical related recipients received bone
marrow. Supportive care practices were per local cen-
ter practice guidelines [37,38].
GVHD Grading and Treatment
Diagnosis, clinical grading, and treatment of acute
and chronic GVHD (aGVHD, cGVHD) were done as
previously described [39-42].
Analyses of Donor Chimerism
Donor engraftment was confirmed by chimerism
analyses [43-46]. Rejection was defined as the detec-
tion of #5% donor T cells (CD3) for HLA-matched
related, unrelated, and HLA-haploidentical related
(FHCRC) recipients and \5% donor cells after
HCT for the HLA-haploidentical related recipients
at SKCCC.
1282 Biol Blood Marrow Transplant 14:1279-1287, 2008L. M. Burroughs et al.Statistical Methods
Overall (OS) and progression-free survival (PFS)
were estimated by the Kaplan-Meier method. Cumu-
lative incidence estimates were calculated for relapse,
NRM, and aGVHD and cGVHD.Hazard ratios com-
paring rates of events between groups and adjusting for
other risk factors were estimated from Cox regression
models. All models were adjusted for disease burden
$5 or\5 cm tumor mass/lymphadenopathy, disease
status at HCT (in CR, PR, or untested relapse/refrac-
tory), and HCT-CI (0-1 versus $2).
RESULTS
Engraftment
The median absolute neutrophil nadirs for HLA-
matched related, unrelated, and HLA-haploidentical
related recipients were 672 (range: 0-3460), 400
(range: 0-1450), and 0 (range: 0-140) cells/mL and oc-
curred at medians of 14 (range: 7-96), 12 (range: 3-93),
and 9 (range: 1-14) days, respectively.
Median percentages of peripheral blood donor
CD31 T cell chimerism at days 28, 56, and 84 were
92%, 94%, and 95% for HLA-matched related recip-
ients and 95%, 98%, and 99% for unrelated recipients.
Median percentages of chimerism at 1 and 2 months
after HCT were 100 and 100, respectively for the
HLA-haploidentical related recipients. None of the
90 patients rejected their grafts.
Sixty-six percent HLA-matched related, 75% un-
related, and 93% HLA-haploidentical related recipi-
ents required red blood cell transfusions, and the
median number of red blood cell units given were 6
(range: 1-24), 6 (range: 2-21), and 4 (range: 2-17), re-
spectively. In addition, 32% HLA-matched related,
33% unrelated, and 82% HLA-haploidentical related
recipients required platelet transfusions, and the me-
dian number of platelet transfusions given were 7
(range: 1-16), 4 (range: 1-23), and 15 (range: 2-100),
respectively.
GVHD
The incidences of aGVHD grades II-IV and III-
IV were 50% and 16% (HLA-matched related), 50%
and 8% (unrelated), and 43% and 11% (HLA-haploi-
dentical related) (Figure 1A and B and Table 2). With
a median follow up of 25 (range: 4-87) months for liv-
ing patients; the 2-year incidences of extensive
cGVHD for HLA-matched related, unrelated, and
HLA-haploidentical related recipients were 50%,
63%, and 35%, respectively (Figure 1C). The median
days to development of grade II-IV aGVHD and
cGVHD were 39 and 154 (HLA-matched related),
28 and 198 (unrelated), and 34 and 177 (HLA-haploi-
dentical related), respectively.When included in amul-tivariate model that adjusted for disease burden (tumor
mass/lymphadenopathy $5 cm or\5 cm), HCT-CI
(0-1, 21), and disease status at time of HCT (CR,
PR, untested relapse/refractory), there was a trend to-
ward lower incidences of extensive cGVHD in the
HLA-haploidentical related recipients compared to
the HLA-matched related (hazard ratio [HR] 5 0.54,
95% CI [0.2-1.2], P 5 .14) and unrelated (HR 5
0.45, 95% CI [0.2-1.0], P 5 .06) recipients. However,
multivariate analysis demonstrated that the recipients
of HLA-haploidentical related grafts were more
successful in discontinuing immunosuppression com-
pared to the HLA-matched related (HR 5 2.46,
95% CI [1.0-5.8], P 5 .04) and unrelated
(HR 5 3.05, 95% CI [1.1-8.1], P 5 .03) recipients.
Disease Response
Of the 11 HLA-matched related, 5 unrelated, and
6 HLA-haploidentical related recipients in CR before
HCT, 5, 2, and 1 relapsed after HCT, respectively. Of
the patients with measurable disease before HCT, 11/
27 (41%) HLA-matched related, 12/19 (63%) unre-
lated, and 19/22 (86%) HLA-haploidentical related
recipients achieved initial CR or PR after HCT; how-
ever, 2, 8, and 7 recipients subsequently relapsed or
progressed, respectively. One HLA-matched related
recipient who was in PR before HCT progressed 1
month after HCT and subsequently entered CR fol-
lowing radiation therapy; CR is sustained now 3.4
years. For patients with measurable disease before
HCT who entered CR following HCT, the median
times to CR were 86 (range: 55-185), 83 (range: 55-
195), and 62 (range: 29-281) days for HLA-matched
related, unrelated and HLA-haploidentical related re-
cipients, respectively. In univariate analysis, there
were no differences in OS, PFS, or incidences of re-
lapse based on disease status at time of HCT. Of the
11 patients with disease burden $5 cm at time of
HCT, 4 were in CR (1 HLA-matched related, 3
HLA-haploidentical related), 2 had stable disease,
and 5 had relapsed/refractory disease at time of last
follow-up.
Disease Progression
The 2-year cumulative incidences of relapse/dis-
ease progression were 56% (HLA-matched related),
63% (unrelated), and 40% (HLA-haploidentical re-
lated) (Figure 2 and Table 2). There were significantly
decreased risks of relapse for HLA-haploidentical re-
lated recipients compared to HLA-matched related
(HR5 0.35, 95% CI [0.2-0.8], P5 .01) and unrelated
(HR 5 0.43, 95% CI [0.2-0.9], P 5 .03) recipients.
There were no differences in risks of relapse between
HLA-matched related and unrelated recipients. The
median times to relapse/progression for the HLA-
matched related, unrelated, and HLA-haploidentical
Biol Blood Marrow Transplant 14:1279-1287, 2008 1283Nonmyeloablative HCT for Advanced Hodgkin LymphomaFigure 1. Incidences of (A) grade II-IV aGVHD, (B) grade III-IV aGVHD, and (C) extensive cGVHD according to donor type.related recipients were 119 (range: 29-2632), 279
(range: 4-849), and 164 (range: 28-1069) days, respec-
tively. Six HLA-matched related and 4 unrelated re-
cipients with disease relapse/progression failed to
respond to donor lymphocyte infusion (DLI). One
HLA-haploidentical related recipient with disease
progression received DLI  3 and is alive in CR 4.8
years after HCT.
Survival and NRM
The 2-year OS and PFS were 53% and 23%
(HLA-matched related), 58% and 29% (unrelated),
and 58% and 51% (HLA-haploidentical related), re-
spectively after HCT (Figure 3A and 3B, and Table2). Although multivariate analysis did not demonstrate
any significant differences in OS between the 3 groups,
significantly improved PFS was found for HLA-hap-
loidentical related recipients compared to HLA-
matched related (HR 5 0.30; 95% CI [0.1-0.6], P 5
.0008) and unrelated (HR 5 0.46, 95% CI [0.2-0.9],
P 5 .03) recipients. There were no significant differ-
ences in PFS among HLA-matched related compared
to the unrelated recipients. Day 200 and 2-year NRM
were 16% and 21% (HLA-matched related), 0% and
8% (unrelated), and 0% and 9% (HLA-haploidentical
related). NRM was significantly lower for HLA-
haploidentical related (HR 5 0.14, 95% CI [0.0-0.7],
P5 .02) recipients compared toHLA-matched related
recipients (Figure 4). Although not significant, there
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ents (HR5 0.23, 95%CI [0.0-1.2], P5 .08) compared
to related recipients. There were no significant differ-
ences in NRM between the unrelated and HLA-
haploidentical related recipients. The primary causes
of NRM for all 3 groups were GVHD 6 infections
(6/8 HLA-matched related, 2/2 unrelated, 2/2 HLA-
haploidentical related recipients).
DISCUSSION
Successful treatments in patients withHLwho have
relapsed or refractory disease after autologousHCT are
limited, andoutcomeshavebeenpoor. SecondHCTus-
ingmyeloablative conditioninghas been associatedwith
highNRMand relapse rates with only small numbers of
patients achieving long-term remissions and cures.Here
we compared outcomes of high-risk patients with HL
who received nonmyeloablative conditioning before
HLA-matched related, unrelated, orHLA-haploidenti-
cal related grafts.Most patients were heavily pretreated,
and had failed both high-dose autologous HCT and lo-
cal radiation therapy. The 3 patient groups had similar
distributions of HCT-CI scores. However, more unre-
lated andHLA-haploidentical related recipients had re-
lapsed or refractory disease compared toHLA-matched
related recipients.
We found no significant differences in OS among
the 3 groups. However, day 200 and 2-year NRM
were lowest among unrelated andHLA-haploidentical
related recipients. Although ‘‘higher,’’ the NRM for
the HLA-matched related group was actually similar
to our experience in patients with aggressive non
Hodgkin lymphoma [47,48] and other hematologic
malignancies [20]. In contrast, the NRM seen in recip-
ients of alternative donor grafts was unexpectedly low
compared to what has been previously seen in larger
studies [20,33]. This finding could be because of the
small numbers of patients studied.
Figure 2. Incidences of relapse according to donor type.We also found no differences in the incidences of
severe grade III-IV aGVHD or cGVHD between the
groups. Despite greater HLA-disparity in the HLA-
haploidentical related recipients, the incidences of
severe aGVHD and extensive cGVHD were quite
Figure 3. Incidences of (A) OS, and (B) PFS according to donor type.
Table 2. Outcomes by Donor Type
HLA-Matched
Related
(n 5 38)
Unrelated
(n 5 24)
HLA-Haploidentical
related (n528)
Follow-up for surviving patients
Median, in
months (range)
24 (11-87) 38 (20-60) 22 (4-62)
GVHD
Acute
Grade II-IV
50% 50% 43%
Grade III-IV 16% 8% 11%
2-Year extensive
chronic
50% 63% 35%
Day 200 NRM 18%* 0% 0%
2-year
Overall survival 53% 58% 58%
NRM 21%* 8% 9%
Relapse/progressive
disease
56% 63% 40%*
PFS 23% 29% 51%*
PFS indicates progression-free survival; NRM, nonrelapse mortality;
GVHD, graft-versus-host disease.
*Adjusted hazard ratio analysis demonstrated statistically significant dif-
ferences (see text).
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intensity regimens using HLA-matched related and
unrelated donors, supporting the hypothesis that post-
transplantation Cy is important in killing T cell clones
that are involved in the development of GVHD [49].
However, it should also be noted that HLA-haploi-
dentical related recipients received bone marrow,
which generally causes less cGVHD compared to
PBSC, which was the stem cell product among HLA-
matched related and unrelated recipients [50-52].
We also found lower rates of relapse and better
PFS at 2 years for the HLA-haploidentical related re-
cipients. The greater antitumor effects noted in the
HLA-haploidentical related group may in part be
due to the slightly increased intensity of the condition-
ing regimen and in part, because of the HLA disparity
and, thereby greater GVL effects. However, the same
was not true for the unrelated donor group who actu-
ally had slightly higher rates of relapse at 2 years com-
pared to the HLA-matched related group. Although
there were more patients in both the unrelated and
HLA-haploidentical related groups with relapsed/re-
fractory disease before HCT, we did not find a differ-
ence in outcome based on disease status to account for
the differences in relapse.
Several groups of investigators have reported on
the use of nonmyeloablative/reduced intensity condi-
tioning (RIC) regimens with HLA-matched related
or unrelated grafts for treatment of relapsed/refractory
HL. Direct comparisons between studies are difficult
given the heterogeneity of the patient populations
and preparative regimens used; however, several points
are worth discussing. Peggs et al. [14] published results
on 49 patients conditioned with Flu, Mel and alemtu-
zumab and compared outcomes based on donors
(HLA-matched related or unrelated). Day 100 and 2-
year NRM were low (4% and 16%, respectively). Dis-
ease relapse/progression occurred in 43% of patients
and 33% required DLI because of progressive disease.
Figure 4. Incidences of NRM according to donor type.The projected 4-year PFS was 32%. Anderlini et al. [9]
reported on 40 patients who were primarily condi-
tioned with a combination of either Flu and Cy 6
ATG, or Flu and Mel, followed by HLA-matched re-
lated or unrelated grafts. With a median follow-up of
13 months, the 18-month OS, incidences of relapse,
and PFS were 61%, 55%, and 32%, respectively.
Day 100 and 18-month TRM were 5% and 22%,
respectively. In contrast to our study, all patients
enrolled had chemosensitive or stable disease after sal-
vage therapy; those with progressive disease were
treated off protocol that may have contributed to the
slightly better PFS seen in their study. Anderlini
et al. [53] published an update on Flu/Mel group
(n 5 58) and found similar OS (64%), disease re-
lapse/progression (55%), and PFS (32%) at a longer
follow-up (median 2 years).
Recently, Majhail et al. [54] reported on 21
patients with HL who were conditioned with either
busulfan (Bu), Flu, and 2 Gy TBI, or Cy, fludarabine,
and 2 Gy TBI, followed by either HLA-matched sib-
ling (n 5 12) or unrelated umbilical cord blood
(UCB; n 5 9) grafts. With a median follow-up of 17
(UCB) and 24 (HLA-matched sibling) months, the
2-year OS and PFS were 51% and 25% (UCB) and
48% and 20% (HLA-matched sibling), respectively.
Day 180 treatment related mortality (TRM) were
22% (UCB) and 25% (HLA-matched sibling).
RIC/nonmyeloablative conditioning regimens have
expanded treatment options for very advanced high-risk
patients with HL. Importantly, our results and those of
others demonstrated significant decreases in both
early and late NRM compared to HCT using mye-
loablative regimens. Our data suggest that salvage
allogeneic HCT using nonmyeloablative condition-
ing provides antitumor activity in patients with
very advanced disease. Importantly, alternative donor
sources are a viable option particularly for those
patients who may have a limited window of opportu-
nity to proceed to HCT. Similar to what others have
reported, relapse/progression continues to be the
major problem regardless of stem cell source in
these heavily pretreated patients. Inclusion of agents
that more specifically target HL is needed. Possibil-
ities include anti-CD30 antibodies or antibody/drug
conjugates, histone deacetylase inhibitors, or radiola-
beled antibodies [55]. Ultimately, separation of
GVHD activity from graft-versus-tumor responses
through the identification of minor antigen poly-
morphisms or tumor specific antigens is needed to
provide safer and more effective therapy.
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